Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MAGENTA THERAPEUTICS, INC.

(MGTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
6.57(c) 6.06(c) 5.72(c) 5.63(c) 5.5(c) Last
141 407 103 470 258 672 390 708 346 339 Volume
+0.77% -7.76% -5.61% -1.57% -2.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -70,7 M - -
Net cash position 2021 174 M - -
P/E ratio 2021 -4,30x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -89,1 M - -
Net cash position 2022 88,9 M - -
P/E ratio 2022 -3,77x
Yield 2022 -
Capitalization 321 M 321 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 73
Free-Float 91,9%
More Financials
Company
Magenta Therapeutics, Inc is a clinical-stage biotechnology company. The Company is developing medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. The Company developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for... 
More about the company
Ratings of Magenta Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about MAGENTA THERAPEUTICS, INC.
11/08B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-1..
MT
11/04Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outper..
MT
11/04Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
BU
11/04Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Condi..
BU
11/04MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/04Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights - F..
PU
11/04Magenta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, ..
AQ
10/04MAGENTA THERAPEUTICS : Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
BU
10/04Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
CI
09/21MAGENTA THERAPEUTICS : to Participate in 2021 Cantor Virtual Global Healthcare Conference
BU
09/20Top Premarket Decliners
MT
09/15MAGENTA THERAPEUTICS : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study i..
MT
09/15Magenta Therapeutics Gets IND Clearance for MGTA-117
DJ
09/15MAGENTA THERAPEUTICS : Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical..
BU
More news
News in other languages on MAGENTA THERAPEUTICS, INC.
09/09TScan Therapeutics nomme Zoran Zdraveski au poste de directeur des affaires juridiques
2020ORIGINAL-RESEARCH : HEIDELBERG PHARMA AG (von EQUITS GmbH): Kaufen
2020ORIGINAL-RESEARCH : HEIDELBERG PHARMA AG (von EQUITS GmbH): Kaufen
More news
Analyst Recommendations on MAGENTA THERAPEUTICS, INC.
More recommendations
Chart MAGENTA THERAPEUTICS, INC.
Duration : Period :
Magenta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAGENTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,50 $
Average target price 13,17 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Jason Gardner President, Chief Executive Officer & Director
Stephen Frank Mahoney COO, CFO, Treasurer & Chief Accounting Officer
Alison Francis Lawton Chairman
Lisa M. Olson Chief Scientific Officer & Head-Research
David Nichols Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
MAGENTA THERAPEUTICS, INC.-29.85%321
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.30.33%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122